Tumor suppressor p53 can transcriptionally activate downstream genes in response to
stress, and then regulate the cell cycle, DNA repair, metabolism, angiogenesis, apoptosis …

The E26 transformation specific (ETS) family comprises 28 transcription factors, the majority
of which are involved in tumor initiation and development. Serving as a group of functionally …

Improved understanding of TP53 biology and the clinicopathological features of TP53-
mutated myeloid neoplasms has led to the recognition of TP53-mutated acute myeloid …

Systemic immune status influences the elimination of tumor cells. However, it remains
unclear how chronic inflammation in allergic diseases affects the tumor microenvironment …

Pharmaceutical development of cancer therapeutics is a dynamic area of research. Even
after decades of intensive work, cancer continues to be a dreadful disease with an ever …

Systemic therapy options for urothelial carcinoma have expanded in recent years, with both
immunotherapy and cytotoxic chemotherapy being widely available. However, we lack …

The high heterogeneity of breast cancer (BC) caused by pathogenic gene mutations poses a
challenge to immunotherapy, but the underlying mechanism remains unknown. The …

Increasing evidence suggests that key cancer-causing driver genes continue to exert a
sustained influence on the tumor microenvironment (TME), highlighting the importance of …

Background: Serine protease inhibitor E (SERPINE) family genes participate in the tumor
growth, cancer cell survival and metastasis. However, the SERPINE family members role in …

Genetic alterations that affect the function of p53 tumor suppressor have been extensively
investigated in myeloid neoplasms, revealing their significant impact on disease …